新华制药
(000756)
| 流通市值：70.04亿 | | | 总市值：106.73亿 |
| 流通股本：4.48亿 | | | 总股本：6.82亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,474,697,457.66 | 8,100,844,707.33 | 6,497,534,830.57 | 4,672,269,049.13 |
| 营业收入 | 2,474,697,457.66 | 8,100,844,707.33 | 6,497,534,830.57 | 4,672,269,049.13 |
| 二、营业总成本 | 2,328,929,009.3 | 7,530,904,783.94 | 6,039,257,829.4 | 4,311,750,429.21 |
| 营业成本 | 1,795,729,697.76 | 5,709,142,351 | 4,607,407,658.38 | 3,281,046,254.21 |
| 税金及附加 | 18,434,857.09 | 92,175,276.66 | 78,604,110.04 | 60,476,643.03 |
| 销售费用 | 291,064,033.27 | 780,171,394.31 | 643,446,889.77 | 487,038,936.17 |
| 管理费用 | 78,840,015.11 | 513,824,781.93 | 359,156,212.14 | 246,316,699.21 |
| 研发费用 | 141,905,763.44 | 419,239,700.9 | 341,281,879.49 | 235,529,909.24 |
| 财务费用 | 2,954,642.63 | 16,351,279.14 | 9,361,079.58 | 1,341,987.35 |
| 其中:利息费用 | 9,217,078.08 | 41,148,585.76 | 31,708,976.46 | 21,488,813.56 |
| 其中:利息收入 | 2,881,003.92 | 12,300,491.07 | 9,710,348.87 | 6,731,842.63 |
| 加:投资收益 | 1,188,728.16 | 9,583,372.02 | 9,689,034.62 | 8,286,352.28 |
| 资产处置收益 | 845,111.01 | 8,733,639.41 | 8,280,514.96 | 1,274,182.44 |
| 资产减值损失(新) | - | -69,282,694.12 | -44,340,776.07 | -44,340,776.07 |
| 信用减值损失(新) | 70,000 | -10,294,468.42 | -3,088,314.61 | -3,477,647.35 |
| 其他收益 | 22,684,697.21 | 25,902,239.33 | 18,052,760.69 | 11,695,552.06 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 170,556,984.74 | 534,582,011.61 | 446,870,220.76 | 333,956,283.28 |
| 加:营业外收入 | 193,820.84 | 5,537,126.16 | 4,193,692.89 | 632,015.65 |
| 减:营业外支出 | 1,979,283.56 | 7,433,412.75 | 4,587,146.8 | 2,642,486.67 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 168,771,522.02 | 532,685,725.02 | 446,476,766.85 | 331,945,812.26 |
| 减:所得税费用 | 23,507,423.62 | 26,578,700.01 | 46,187,008.38 | 56,265,379.99 |
| 六、净利润 | 145,264,098.4 | 506,107,025.01 | 400,289,758.47 | 275,680,432.27 |
| 持续经营净利润 | 145,264,098.4 | 506,107,025.01 | 400,289,758.47 | 275,680,432.27 |
| 归属于母公司股东的净利润 | 141,879,437.62 | 496,512,201.25 | 391,968,372.92 | 269,807,157.85 |
| 少数股东损益 | 3,384,660.78 | 9,594,823.76 | 8,321,385.55 | 5,873,274.42 |
| (一)基本每股收益 | 0.21 | 0.74 | 0.58 | 0.4 |
| (二)稀释每股收益 | 0.21 | 0.72 | 0.57 | 0.39 |
| 八、其他综合收益 | 815,327.77 | 1,736,014.71 | 24,317,701.91 | 13,873,006.87 |
| 归属于母公司股东的其他综合收益 | 807,373.6 | 1,491,268.41 | 23,870,787.7 | 13,346,960.91 |
| 九、综合收益总额 | 146,079,426.17 | 507,843,039.72 | 424,607,460.38 | 289,553,439.14 |
| 归属于母公司股东的综合收益总额 | 142,686,811.22 | 498,003,469.66 | 415,839,160.62 | 283,154,118.76 |
| 归属于少数股东的综合收益总额 | 3,392,614.95 | 9,839,570.06 | 8,768,299.76 | 6,399,320.38 |
| 公告日期 | 2024-04-26 | 2024-03-29 | 2023-10-28 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |